HATO Medical Technologies
Odense · Founded 2020
About HATO Medical Technologies
Imagine a world where 32% of all deaths could be prevented with accurate and timely diagnoses. Unfortunately, misdiagnoses of cardiovascular disease (CD) are all too common in pre-specialist settings. Often, the first test to investigate the heart of a potential CD patient is an electrocardiogram (ECG) performed and analyzed by non-specialists. But what if these healthcare professionals had access to a tool that could make interpreting ECGs easy and accurate? Our survey of health professionals revealed that less than half felt confident interpreting ECGs, 60% found it difficult to diagnose based on ECG recordings and only 2% trusted the suggestions from their current device. HATO utilizes artificial intelligence (AI) to analyze electrocardiogram (ECG) recordings in real-time and provide accurate and timely diagnoses of cardiovascular diseases. Our agnostic software solution utilizes deep learning to quickly identify and understand abnormalities in the heart, and agnostic software provides healthcare professionals with a real-time view of the patient's heart to assist in locating abnormalities and reacting quickly in critical situations. This helps to ensure rapid and accurate decision-making for appropriate patient visitation, triage, and treatment, as well as for healthcare professionals who may not have extensive knowledge in cardiology.
Company Facts
- Founded: 2020
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $161.3K
- Funding stage: Seed
- Last round: Grant (May 2023)
- Website: https://hatomedicaltechnologies.com
- Phone: +4571787166
Industries & Categories
Artificial Intelligence (AI), B2B, Big Data, Health Care, Machine Learning
Social Profiles
Canonical: https://fsome.com/organization/hato-medical-technologies-188772 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.